Therapeutics aiming to reverse T‐cell exhaustion by targeting PD‐1 are becoming popular, and a recent paper highlighted that patients with cancer treated with anti‐PD‐1 immunotherapy had an increase in proliferation within their PD‐1 expressing CD4+ T follicular helper cells.34 This evidence concerns the gene PDCD1 and cancer.